ZA200307829B - Modified human granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity. - Google Patents
Modified human granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity. Download PDFInfo
- Publication number
- ZA200307829B ZA200307829B ZA200307829A ZA200307829A ZA200307829B ZA 200307829 B ZA200307829 B ZA 200307829B ZA 200307829 A ZA200307829 A ZA 200307829A ZA 200307829 A ZA200307829 A ZA 200307829A ZA 200307829 B ZA200307829 B ZA 200307829B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acid
- molecule
- peptide
- binding
- csf
- Prior art date
Links
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims description 47
- 230000005847 immunogenicity Effects 0.000 title claims description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title description 40
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 title description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 161
- 230000027455 binding Effects 0.000 claims description 83
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 125000000539 amino acid group Chemical group 0.000 claims description 44
- 108091054438 MHC class II family Proteins 0.000 claims description 43
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 32
- 239000003446 ligand Substances 0.000 claims description 31
- 230000006870 function Effects 0.000 claims description 29
- 102000043131 MHC class II family Human genes 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 230000004071 biological effect Effects 0.000 claims description 19
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 17
- 230000004075 alteration Effects 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 238000000126 in silico method Methods 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000009149 molecular binding Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 7
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 52
- 229940024606 amino acid Drugs 0.000 description 45
- 125000004429 atom Chemical group 0.000 description 40
- 229910052739 hydrogen Inorganic materials 0.000 description 28
- 239000001257 hydrogen Substances 0.000 description 28
- 230000003993 interaction Effects 0.000 description 21
- 230000028993 immune response Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 125000001931 aliphatic group Chemical group 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000205 computational method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 102000046157 human CSF2 Human genes 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000002884 conformational search Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100039350 Interferon alpha-7 Human genes 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000255964 Pieridae Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000012900 molecular simulation Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000386 donor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105775 | 2001-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307829B true ZA200307829B (en) | 2004-07-21 |
Family
ID=8176721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307829A ZA200307829B (en) | 2001-03-08 | 2003-10-07 | Modified human granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7208147B2 (fr) |
| EP (1) | EP1366074B1 (fr) |
| JP (1) | JP2004535777A (fr) |
| KR (1) | KR20030082962A (fr) |
| CN (1) | CN1494551A (fr) |
| AT (1) | ATE339446T1 (fr) |
| BR (1) | BR0207945A (fr) |
| CA (1) | CA2439926A1 (fr) |
| DE (1) | DE60214682T2 (fr) |
| HU (1) | HUP0303429A3 (fr) |
| MX (1) | MXPA03008032A (fr) |
| PL (1) | PL362986A1 (fr) |
| RU (1) | RU2003129058A (fr) |
| WO (1) | WO2002070548A2 (fr) |
| ZA (1) | ZA200307829B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| AU2013201228B2 (en) * | 2006-02-08 | 2016-01-21 | Eisai, Inc. | Antigenic gm-csf peptides and antibodies to gm-csf |
| US8252897B2 (en) * | 2007-06-21 | 2012-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| US8470314B2 (en) * | 2008-02-29 | 2013-06-25 | Angelica Therapeutics, Inc. | Modified toxins |
| CN104093414A (zh) | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | 噬菌体的p3作为淀粉样蛋白结合剂的用途 |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| CA2902905A1 (fr) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Toxines modifiees |
| EA030389B1 (ru) | 2013-05-28 | 2018-07-31 | Проклара Байосайенсиз, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ |
| EP3227313B1 (fr) | 2014-12-03 | 2022-02-09 | Proclara Biosciences, Inc. | Polypeptides comportant une séquence d'acides aminés modifiée de la protéine g3p d'un bactériophage, dépourvue de signal de glycosylation |
| TW201808987A (zh) | 2016-06-08 | 2018-03-16 | 健生生物科技公司 | Ｇｍ－ｃｓｆ變體及使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| DE69833755T2 (de) * | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
-
2002
- 2002-02-28 AT AT02732448T patent/ATE339446T1/de not_active IP Right Cessation
- 2002-02-28 CA CA002439926A patent/CA2439926A1/fr not_active Abandoned
- 2002-02-28 JP JP2002569867A patent/JP2004535777A/ja active Pending
- 2002-02-28 DE DE60214682T patent/DE60214682T2/de not_active Expired - Lifetime
- 2002-02-28 RU RU2003129058/13A patent/RU2003129058A/ru not_active Application Discontinuation
- 2002-02-28 HU HU0303429A patent/HUP0303429A3/hu unknown
- 2002-02-28 EP EP02732448A patent/EP1366074B1/fr not_active Expired - Lifetime
- 2002-02-28 KR KR10-2003-7011661A patent/KR20030082962A/ko not_active Application Discontinuation
- 2002-02-28 MX MXPA03008032A patent/MXPA03008032A/es unknown
- 2002-02-28 US US10/469,900 patent/US7208147B2/en not_active Expired - Fee Related
- 2002-02-28 WO PCT/EP2002/002148 patent/WO2002070548A2/fr active IP Right Grant
- 2002-02-28 CN CNA028060598A patent/CN1494551A/zh active Pending
- 2002-02-28 BR BR0207945-3A patent/BR0207945A/pt not_active IP Right Cessation
- 2002-02-28 PL PL02362986A patent/PL362986A1/xx unknown
-
2003
- 2003-10-07 ZA ZA200307829A patent/ZA200307829B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1366074B1 (fr) | 2006-09-13 |
| KR20030082962A (ko) | 2003-10-23 |
| BR0207945A (pt) | 2004-07-27 |
| US7208147B2 (en) | 2007-04-24 |
| DE60214682T2 (de) | 2007-09-13 |
| WO2002070548A3 (fr) | 2003-05-01 |
| CN1494551A (zh) | 2004-05-05 |
| JP2004535777A (ja) | 2004-12-02 |
| PL362986A1 (en) | 2004-11-15 |
| DE60214682D1 (de) | 2006-10-26 |
| HUP0303429A2 (hu) | 2004-01-28 |
| MXPA03008032A (es) | 2003-12-04 |
| HUP0303429A3 (en) | 2005-12-28 |
| ATE339446T1 (de) | 2006-10-15 |
| US20040092717A1 (en) | 2004-05-13 |
| RU2003129058A (ru) | 2005-04-20 |
| CA2439926A1 (fr) | 2002-09-12 |
| EP1366074A2 (fr) | 2003-12-03 |
| WO2002070548A2 (fr) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1360200A2 (fr) | Facteur neurotrophique bdnf modifie a antigenicite reduite | |
| US20040072219A1 (en) | Modified leptin with reduced immunogenicity | |
| US20040076991A1 (en) | Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity | |
| EP1366074B1 (fr) | Facteur de stimulation des granulocytes et des macrophages (gm-csf) modifie a immunogenicite reduite | |
| EP1357933A2 (fr) | Erythropoietine (epo) modifiee a immunogenicite reduite | |
| US20040121443A1 (en) | Modified protamine with reduced immunogenicity | |
| US20040087503A1 (en) | Modified ciliary neurotrophic factor (cntf ) with reduced immunogenicity | |
| EP1392731B1 (fr) | Facteur de croissance de colonies de granulocytes modifie (fcs-g) a pouvoir antigenique reduit | |
| US20040071688A1 (en) | Modified thrombopoietin with reduced immunogenicity | |
| US20040063634A1 (en) | Modified kertinocyte growth factor (kgf) with reduced immunogenicity | |
| AU2002304824A1 (en) | Modified human granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity | |
| AU2002242715A1 (en) | Modified protamine with reduced immunogenicity | |
| AU2002257579A1 (en) | Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity | |
| AU2002229744A1 (en) | Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity | |
| AU2002249180A1 (en) | Modified keratinocyte growth factor (KGF) with reduced immunogenicity | |
| AU2002238530A1 (en) | Modified human brain-derived neutrophic factor (BDNF) with reduced immunogenicity | |
| AU2002254910A1 (en) | Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity | |
| AU2002250891A1 (en) | Modified leptin with reduced immunogenicity | |
| AU2002250889A1 (en) | Modified erythropoietin (EPO) with reduced immunogenicity |